nach oben

Erschienen in:

01.09.2008

Long-Term Immunological Study in Graves’ Disease Treated with Thyroid Arterial Embolization

verfasst von: Wei Zhao, Bu-Lang Gao, Cang-Zheng Jin, Gen-Fa Yi, Hui-Ying Yang, Hong Li, Dian-Ping Song, Ji-Hong Hu, Yong-Neng Jiang

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to investigate long-term immunological changes after the treatment of Graves’ disease (GD) with thyroid arterial embolization and the effect of thyroid arterial embolization on the body’s immunological functions.

Materials and methods

Forty-one patients with clinically and laboratorily ascertained GD were treated with thyroid arterial embolization and followed up for 3–54 months following embolization. Prior to embolization and at 1, 3, 6, 12, and 36 months following embolization, thyroid autoimmune antibodies were tested respectively, including thyroid stimulating antibody (TSAb), thyrotropin antibody (TRAb), thyroglobulin antibody (TGAb), and thyroid microsomal antibody (TMAb), as well as subgroup lymphocytes of CD16+CD56+, CD19+, CD3+, CD3+CD4+ and CD3+CD8+. The autoimmune status of GD patients prior to embolization and the dynamic changes of the immunological function after embolization were analyzed.

Results

The therapy of thyroid arterial embolization could effectively decrease the activity/titer and positive rate of TRAb and the ratio of CD4+/ CD8+ to normal levels at 6 months following embolization, while the ratio of CD3+CD8+ increased gradually to normal level at 1 year following embolization. In patients with recurrence, TSAb and TRAb remained at a higher level, while the rate of CD3+CD8+ and the ratio of CD4+/CD8+ were not statistically significantly different from those before embolization.

Conclusion

Immunological functional disorder exists in GD patients. The treatment method of thyroid arterial embolization can effectively resume the basic immunological function to normal range while patients with recurrence have no significant improvement, suggesting that thyroid arterial embolization has an effective role in adjusting the immunological function.

Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am 2004;84:849–74.PubMedCrossRef

Cunnien AJ, Hay ID, Gorman CA, Offord KP, Scanlon PW. Radioiodine-induced hypothyroidism in Graves’ disease: factors associated. J Nucl Med 1982;23:978–83.PubMed

Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am 2004;84:833–47.PubMedCrossRef

Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003;111:1897–904.PubMed

Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab: TEM 2001;12:384–90.PubMedCrossRef

Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003;24:802–35.PubMedCrossRef

Weetman AP. Grave’s disease 1835–2002. Horm Res 2003;59(Suppl 1):114–8.PubMedCrossRef

Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J 2007;54:713–20.PubMedCrossRef

Okamoto T, Iihara M, Obara T. Management of hyperthyroidism due to Graves’ and nodular diseases. World J Surg. 2000;24:957–61.PubMedCrossRef

10.

Feldt-Rasmussen U, Glinoer D, Orgiazzi J. Reassessment of antithyroid drug therapy of Graves’ disease. Annu Rev Med 1993;44:323–34.PubMedCrossRef

11.

Toft AD, Weetman AP. Screening for agranulocytosis in patients treated with antithyroid drugs. Clin Endocrinol 1998;49:271.CrossRef

12.

Weetman AP. Graves’ disease. N Engl J Med 2000;343:1236–48.PubMedCrossRef

13.

Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur Jo Endocrinol 2005;153:489–98.CrossRef

14.

Izumi Y, Takeoka K, Amino N. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves’ thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves’ disease. Endocr J 2005;52:493–7.PubMedCrossRef

15.

Levy EG. Treatment of Graves’ disease: the American way. Baillière’s Clin Endocrinol Metab 1997;11:585–95.CrossRef

16.

Galkin EV, Grakov BS, Protopopov AV. First clinical experience of radio-endovascular functional thyroidectomy in the treatment of diffuse toxic goiter. Vestn Rentgenol Radiol. 1994;29–35.

17.

Xiao H, Zhuang W, Wang S, Yu B, Chen G, Zhou M, et al. Arterial embolization: a novel approach to thyroid ablative therapy for Graves’ disease. J Clin Endocrinol Metab 2002;87:3583–9.PubMedCrossRef

18.

Zhao W, Gao BL, Yang HY, Li H, Song DP, Xiang ST, et al. Thyroid arterial embolization to treat Graves’ disease. Acta Radiol 2007;48:186–92.PubMedCrossRef

19.

Trowbridge FL, Matovinovic J, McLaren GD, Nichaman MZ. Iodine and goiter in children. Pediatrics 1975;56:82–90.PubMed

20.

Dworkin HJ, Meier DA, Kaplan M. Advances in the management of patients with thyroid disease. Semin Nucl Med 1995;25:205–20.PubMedCrossRef

21.

Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the radioiodine audit subcommittee of the royal college of physicians committee on diabetes and endocrinology, and the research unit of the royal college of physicians. J R Coll Physicians Lond 1995;29:464–9.PubMed

22.

Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. Jama 1995;273:808–12.PubMedCrossRef

23.

Dai WX, Zhang JD, Zhan SW, Xu BZ, Jin H, Yao Y, et al. Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 2002;49:29–33.PubMed

24.

McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinol Metab Clin N Am 1998;27:73–89.CrossRef

25.

Abe Y. Apoptosis in the pathogenesis of autoimmune thyroid disease. Nippon Rinsho 1999;57:1717–22.PubMed

26.

Giovanella L, Ceriani L, Garancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO). Q J Nucl Med 2001;45:115–9.PubMed

27.

Fisfalen ME, Palmer EM, Van Seventer GA, Soltani K, Sawai Y, Kaplan E, et al. Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab 1997;82:3655–63.PubMedCrossRef

28.

Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995;154:3328–32.PubMed

29.

McIntosh RS, Asghar MS, Weetman AP. The antibody response in human autoimmune thyroid disease. Clin Sci (Lond) 1997;92:529–41.

30.

Song YH, Li Y, Maclaren NK. The nature of autoantigens targeted in autoimmune endocrine diseases. Immunol Today 1996;17:232–8.PubMedCrossRef

31.

Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788–830.PubMedCrossRef

32.

Okita N, Row VV, Volpe R. Suppressor T-lymphocyte deficiency in Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1981;52:528–33.PubMed

33.

Tamai H, Uno H, Hirota Y, Matsubayashi S, Kuma K, Matsumoto H, et al. Immunogenetics of Hashimoto’s and Graves’ diseases. J Clin Endocrinol Metab 1985;60:62–6.PubMedCrossRef

Titel: Long-Term Immunological Study in Graves’ Disease Treated with Thyroid Arterial Embolization
verfasst von: Wei Zhao
Bu-Lang Gao
Cang-Zheng Jin
Gen-Fa Yi
Hui-Ying Yang
Hong Li
Dian-Ping Song
Ji-Hong Hu
Yong-Neng Jiang
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9209-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Sodium Tanshinone IIA Sulfonate Protects Mice From ConA-Induced Hepatitis via Inhibiting NF-κB and IFN-γ/STAT1 Pathways

Use of Sirolimus in IPEX and IPEX-Like Children

Expression of Cytokine mRNA in Lymphocytes of Malnourished Children

Genetic Polymorphisms in the CD40 Ligand Gene and Kawasaki Disease

IL1 Gene Cluster Polymorphisms and Its Haplotypes may Predict the Risk to Develop Invasive Pulmonary Aspergillosis and Modulate C-reactive Protein Level